CL2012003548A1 - Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros. - Google Patents

Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros.

Info

Publication number: CL2012003548A1
Authority: CL; Chile
Prior art keywords: spheres; release; febuxostat; methylthiazol; methylpropoxy
Prior art date: 2010-06-16

Application number

CL2012003548A

Other languages

English (en)

Inventor

Rajneesh Taneja

Vijay Gupte

Majid Vakilynejad

Original Assignee

Takeda Pharmaceuticals North America Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-16

Filing date

2012-12-14

Publication date

2013-09-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45328897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003548(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-14 Application filed by Takeda Pharmaceuticals North America Inc filed Critical Takeda Pharmaceuticals North America Inc

2013-09-06 Publication of CL2012003548A1 publication Critical patent/CL2012003548A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CL2012003548A 2010-06-16 2012-12-14 Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros. CL2012003548A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US35516410P	2010-06-16	2010-06-16

Publications (1)

Publication Number	Publication Date
CL2012003548A1 true CL2012003548A1 (es)	2013-09-06

Family

ID=45328897

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003548A CL2012003548A1 (es)	2010-06-16	2012-12-14	Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros.

Country Status (25)

Country	Link
US (2)	US9248119B2 (es)
EP (1)	EP2582812B1 (es)
JP (2)	JP5865904B2 (es)
KR (1)	KR101872189B1 (es)
CN (1)	CN103210084B (es)
AU (2)	AU2011268445B2 (es)
BR (1)	BR112012032033A2 (es)
CA (1)	CA2801930A1 (es)
CL (1)	CL2012003548A1 (es)
CO (1)	CO6650415A2 (es)
EC (1)	ECSP13012394A (es)
ES (1)	ES2669184T3 (es)
IL (2)	IL223455B (es)
JO (1)	JO3450B1 (es)
MX (2)	MX361138B (es)
MY (1)	MY167126A (es)
NZ (1)	NZ604646A (es)
PE (2)	PE20130574A1 (es)
PH (1)	PH12012502485A1 (es)
RU (1)	RU2602188C2 (es)
SG (1)	SG186301A1 (es)
TW (1)	TW201202249A (es)
UA (1)	UA112632C2 (es)
WO (1)	WO2011159745A1 (es)
ZA (1)	ZA201209386B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5669837B2 (ja) *	2010-06-16	2015-02-18	帝人ファーマ株式会社	放出制御型の有核錠剤
MY160963A (en) *	2010-06-25	2017-03-31	Teijin Pharma Ltd	Sustained-release therapeutic agent for hypertension and renal dysfunction
NZ605562A (en) *	2010-07-09	2013-11-29	Teijin Pharma Ltd	Deuterated benzylbenzene derivatives and methods of use
WO2012153313A1 (en) *	2011-05-11	2012-11-15	Ranbaxy Laboratories Limited	Pharmaceutical composition of febuxostat
WO2012172461A1 (en) *	2011-06-13	2012-12-20	Ranbaxy Laboratories Limited	Pharmaceutical compositions of febuxostat
CA2862602A1 (en) *	2012-01-27	2013-08-01	Teijin Pharma Limited	Therapeutic agent for diabetes
WO2014009817A1 (en) *	2012-07-12	2014-01-16	Alembic Pharmaceuticals Limited	Pharmaceutical composition of febuxostat
CN102973530B (zh) *	2012-12-14	2016-08-03	贵州信邦制药股份有限公司	一种非布索坦双层肠溶片剂及其制备方法
WO2014125504A2 (en) *	2013-02-18	2014-08-21	Hetero Research Foundation	Pharmaceutical compositions of febuxostat
SG11201509738RA (en) *	2013-05-31	2015-12-30	Takeda Pharmaceuticals Usa Inc	Methods of treatment and compositions with xanthine oxidase inhibitors
EP2881116A1 (en) *	2013-12-05	2015-06-10	Ranbaxy Laboratories Limited	Febuxostat composition
AU2015392441A1 (en) *	2015-04-20	2017-11-09	Twi Biotechnology, Inc.	Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) *	2015-04-22	2020-02-11	安成生物科技股份有限公司	含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
WO2017100559A1 (en) *	2015-12-10	2017-06-15	Cogwellin Llc	Controlled release formulations of salicylate-releasing actives
CN106279024B (zh) *	2016-07-19	2018-09-14	华南理工大学	一种黄嘌呤氧化还原酶抑制剂及其制备方法与应用
CN106146419A (zh) *	2016-08-01	2016-11-23	沈阳药科大学	黄嘌呤氧化酶抑制剂
JP6861726B2 (ja) *	2016-11-28	2021-04-21	帝人ファーマ株式会社	糖尿病性腎症の治療薬または予防薬
WO2018228440A1 (zh) *	2017-06-14	2018-12-20	江苏恒瑞医药股份有限公司	一种非布司他控释组合物及其制备方法
CN109721586B (zh) *	2017-10-27	2021-03-02	中国医科大学	一种5-苄基-3-吡啶基-1h-1,2,4-三唑类化合物及其制备方法和用途
CN108484494B (zh) *	2018-06-15	2021-07-30	沈阳药科大学	2-氧代-1,2-二氢吡啶-4-甲酸类化合物
CN108938591A (zh) *	2018-08-21	2018-12-07	天津双硕医药科技有限公司	一种含有非布司他的固体药物组合物
CN109157654B (zh) *	2018-11-06	2021-12-07	苏州大学	Tmx1的用途
CN111662239B (zh) *	2019-03-06	2023-07-28	中国医学科学院药物研究所	1,2,4-三唑类化合物及其制法和药物用途
EP4040991A4 (en) *	2019-10-09	2024-01-24	Mayo Foundation for Medical Education and Research	TREATMENT OF GASTROINTESTINAL DISORDERS
CN113354616B (zh) *	2020-03-05	2024-03-26	中国医学科学院药物研究所	二芳基-1,2,4-三唑类化合物及其制法和药物用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69122084T2 (de)	1990-11-30	1997-04-03	Teijin Ltd., Osaka	2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
AU703609B2 (en)	1995-04-07	1999-03-25	Teijin Limited	Protective agent for organ or tissue
US20010055613A1 (en)	1998-10-21	2001-12-27	Beth A. Burnside	Oral pulsed dose drug delivery system
RU2236847C2 (ru)	1998-11-02	2004-09-27	Илан Корпорейшн, Плк.	Композиции в виде множества частиц с модифицированным высвобождением
ECSP993280A (es)	1999-12-17	2001-07-27		Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos
RU2219957C2 (ru) *	2001-11-19	2003-12-27	Пихлак Андрей Эдуардович	Способ лечения подагры с помощью плазмосорбции
SI21301A (sl)	2002-09-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Farmacevtska oblika z nadzorovanim sproščanjem
CN1713897B (zh)	2002-10-16	2012-07-04	武田药品工业株式会社	控释制剂
MY148805A (en)	2002-10-16	2013-05-31	Takeda Pharmaceutical	Controlled release preparation
US8007827B2 (en)	2004-04-02	2011-08-30	Impax Laboratories, Inc.	Pharmaceutical dosage forms having immediate release and/or controlled release properties
FR2878159B1 (fr) *	2004-11-24	2008-10-17	Flamel Technologies Sa	Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
US8828429B2 (en) *	2005-03-03	2014-09-09	Takeda Pharmaceutical Company Limited	Release-control composition
US8841333B2 (en)	2005-05-09	2014-09-23	Takeda Pharmaceuticals U.S.A., Inc.	Methods for treating nephrolithiasis
FR2891459B1 (fr)	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007073702A2 (es) *	2005-12-29	2007-07-05	Osmotica Corp.	Comprimido multicapa con combinación de triple liberación
RU2508099C2 (ru)	2006-11-13	2014-02-27	Такеда Фармасьютикалз Норт Америка, Инк.	Способы сохранения функции почек с использованием ингибиторов ксантин оксидоредуктазы
US8110226B2 (en) *	2007-07-20	2012-02-07	Mylan Pharmaceuticals Inc.	Drug formulations having inert sealed cores
EP2668953A1 (en) *	2008-05-22	2013-12-04	Bristol-Myers Squibb Company	Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
CN101716132B (zh) *	2008-10-09	2012-01-11	北京方策方程医药科技有限公司	非布索坦肠溶制剂
CN101474175B (zh)	2009-01-20	2014-07-02	重庆医药工业研究院有限责任公司	一种高生物利用度非布司他口服固体制剂及其制备方法
CN101658505A (zh) *	2009-09-29	2010-03-03	北京华禧联合科技发展有限公司	非布索坦的缓释制剂及其制备方法
CN101711743B (zh)	2009-12-04	2011-08-24	山东淄博新达制药有限公司	非布索坦干混悬剂及其制备方法
CN101711751A (zh)	2009-12-04	2010-05-26	山东淄博新达制药有限公司	非布索坦分散片及其制备方法
CN101773498B (zh)	2009-12-30	2012-06-20	青岛黄海制药有限责任公司	一种含有非布司他的口服缓控释制剂的制备方法
MY160963A (en)	2010-06-25	2017-03-31	Teijin Pharma Ltd	Sustained-release therapeutic agent for hypertension and renal dysfunction
NZ605562A (en)	2010-07-09	2013-11-29	Teijin Pharma Ltd	Deuterated benzylbenzene derivatives and methods of use

2011
- 2011-06-15 US US13/160,572 patent/US9248119B2/en not_active Expired - Fee Related
- 2011-06-15 NZ NZ604646A patent/NZ604646A/en not_active IP Right Cessation
- 2011-06-15 PH PH1/2012/502485A patent/PH12012502485A1/en unknown
- 2011-06-15 CN CN201180039889.9A patent/CN103210084B/zh not_active Expired - Fee Related
- 2011-06-15 WO PCT/US2011/040418 patent/WO2011159745A1/en not_active Ceased
- 2011-06-15 SG SG2012091229A patent/SG186301A1/en unknown
- 2011-06-15 KR KR1020127034404A patent/KR101872189B1/ko not_active Expired - Fee Related
- 2011-06-15 TW TW100120925A patent/TW201202249A/zh unknown
- 2011-06-15 UA UAA201300491A patent/UA112632C2/uk unknown
- 2011-06-15 PE PE2012002433A patent/PE20130574A1/es active IP Right Grant
- 2011-06-15 MX MX2016002326A patent/MX361138B/es unknown
- 2011-06-15 PE PE2016002815A patent/PE20170306A1/es unknown
- 2011-06-15 EP EP11796331.4A patent/EP2582812B1/en not_active Not-in-force
- 2011-06-15 RU RU2013101767/15A patent/RU2602188C2/ru not_active IP Right Cessation
- 2011-06-15 BR BR112012032033A patent/BR112012032033A2/pt not_active Application Discontinuation
- 2011-06-15 ES ES11796331.4T patent/ES2669184T3/es active Active
- 2011-06-15 MX MX2012014836A patent/MX336607B/es unknown
- 2011-06-15 JP JP2013515463A patent/JP5865904B2/ja not_active Expired - Fee Related
- 2011-06-15 CA CA2801930A patent/CA2801930A1/en not_active Abandoned
- 2011-06-15 AU AU2011268445A patent/AU2011268445B2/en not_active Ceased
- 2011-06-15 MY MYPI2012701119A patent/MY167126A/en unknown
- 2011-06-15 JO JOP/2011/0194A patent/JO3450B1/ar active
2012
- 2012-12-05 IL IL223455A patent/IL223455B/en active IP Right Grant
- 2012-12-11 ZA ZA2012/09386A patent/ZA201209386B/en unknown
- 2012-12-14 CL CL2012003548A patent/CL2012003548A1/es unknown
- 2012-12-14 CO CO12227085A patent/CO6650415A2/es unknown
2013
- 2013-01-16 EC ECSP13012394 patent/ECSP13012394A/es unknown
2015
- 2015-07-15 AU AU2015204313A patent/AU2015204313B2/en not_active Ceased
- 2015-12-25 JP JP2015253745A patent/JP2016104774A/ja active Pending
2016
- 2016-01-29 US US15/010,212 patent/US9937157B2/en not_active Expired - Fee Related
2019
- 2019-01-23 IL IL264441A patent/IL264441A/en unknown

Also Published As

Publication number	Publication date
MX336607B (es)	2016-01-25
US9248119B2 (en)	2016-02-02
ECSP13012394A (es)	2013-04-30
WO2011159745A1 (en)	2011-12-22
MX361138B (es)	2018-11-28
JP2013528651A (ja)	2013-07-11
AU2011268445B9 (en)	2015-05-07
PE20170306A1 (es)	2017-05-06
AU2011268445A1 (en)	2013-01-10
RU2602188C2 (ru)	2016-11-10
AU2011268445B2 (en)	2015-05-07
UA112632C2 (uk)	2016-10-10
ZA201209386B (en)	2016-08-31
EP2582812A4 (en)	2013-12-04
HK1187371A1 (zh)	2014-04-04
ES2669184T3 (es)	2018-05-24
MY167126A (en)	2018-08-13
PH12012502485A1 (en)	2022-10-05
CO6650415A2 (es)	2013-04-15
AU2015204313B2 (en)	2017-11-16
US20160317505A1 (en)	2016-11-03
IL223455B (en)	2019-01-31
BR112012032033A2 (pt)	2017-10-31
NZ604646A (en)	2014-11-28
JP2016104774A (ja)	2016-06-09
CA2801930A1 (en)	2011-12-22
RU2013101767A (ru)	2014-07-27
JP5865904B2 (ja)	2016-02-17
KR101872189B1 (ko)	2018-06-29
TW201202249A (en)	2012-01-16
EP2582812A1 (en)	2013-04-24
IL264441A (en)	2019-02-28
EP2582812B1 (en)	2018-01-24
CN103210084A (zh)	2013-07-17
KR20130129826A (ko)	2013-11-29
PE20130574A1 (es)	2013-06-01
US20110311620A1 (en)	2011-12-22
MX2012014836A (es)	2013-05-01
CN103210084B (zh)	2016-04-20
US9937157B2 (en)	2018-04-10
JO3450B1 (ar)	2020-07-05
AU2015204313A1 (en)	2015-08-06
SG186301A1 (en)	2013-02-28

Publication	Publication Date	Title
CL2012003548A1 (es)	2013-09-06	Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros.
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
IL219053B (en)	2018-07-31	Pirfenidone for use while avoiding, contraindicating or discontinuing cyp1a2 inhibitors
CL2014001157A1 (es)	2015-01-16	Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato.
BR112014011671A2 (pt)	2017-05-30	composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0919937A2 (pt)	2016-02-16	composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112014010179A2 (pt)	2017-04-25	composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
HUE041944T2 (hu)	2019-06-28	Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére
EP2751086A4 (en)	2015-09-16	KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF
BR112013026341A2 (pt)	2019-09-24	composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
WO2012142498A3 (en)	2012-12-06	Mif inhibitors and their uses
BRPI1008383A2 (pt)	2016-02-23	composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BR112014005235A2 (pt)	2017-04-11	composto heterocíclico, composição farmacêutica, agente profilático e/ou terapêutico, e, método para prevenir e/ou tratar uma doença neurológica central
PT2753334T (pt)	2022-11-03	Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos
BRPI0810893A2 (pt)	2014-10-29	Uso de inibidor de tnf-alfa a um anti-histamínico para tratar rinite alérgica e conjuntivite, e composição farmacêutica compreendendo os referidos compostos.
BR112012026570A2 (pt)	2017-12-19	composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BRPI0922619A2 (pt)	2016-09-13	compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento
EP2750677A4 (en)	2015-05-27	KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF
BR112014006420A2 (pt)	2017-04-11	compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
CL2015000732A1 (es)	2015-08-07	Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
BR112013010738A2 (pt)	2016-07-12	composto, composição farmacêutica, e, método para tratar uma infecção viral
CL2012003523A1 (es)	2014-02-14	Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
IL206450A0 (en)	2010-12-30	Use of an acetylsalicylic acid salt for the treatment of viral infections